Owning and operating your own business is the American dream. Keeping track of your workforce while they are out on calls or delivering products and services is essential for maintaining a healthy profit margin and providing superior customer service. GTX Corp. (OTC: GTXO), through wholly owned subsidiary LOCiMOBILE, Inc., recently announced the launch of its new and improved Track My Workforce App and backend portal, which helps alleviate some of the concerns a business owner has as it relates to his/her mobile workforce.

The app is specifically designed for small- and medium-sized businesses, enabling them to track their mobile workforce using GPS technology via a simple download of the Track My Workforce mobile app on their smartphones or tablets using iOS or Android technology. The app can be downloaded for free during a two-week trial period and then changes to a very affordable price of $5 per month per user. This sense of security is necessary for business owners to effectively keep track of their assets and monitor them while they are out representing the company.

Food delivery, pharmaceutical sales, construction workers, caregivers, government workers, and hunting outfitters are just a few of the businesses that would benefit from being able to make sure their employees are where they are supposed to be when they are supposed to be there and doing what they are supposed to be doing. GTXO provides a very affordable, tacit, and easy to use means of quality control with its innovative Track My Workforce app.

GTXO already has more than 2 million downloads across 162 countries. With more than 30 million small- and medium-sized business in the U.S. and 200 million worldwide, the market is substantial, to say the least. Also, with GTXO’s subscription-based recurring revenue model, numbers are only going to get better over time.

For more information, visit www.gtxcorp.com

Let us hear your thoughts: GTX Corp. Message Board

Oakridge Global Energy Solutions, Inc. (OTCQB: OGES) yesterday announced that it has received a supplier agreement from Maritime Tactical Systems, Inc. (MARTAC), an industry leader in the unmanned maritime market space.

MARTAC is a Melbourne, Florida-based company that designs and produces the Man-Portable Tactical Autonomous Systems (MANTIS), which can top 75 miles per hour. These vehicles are used in numerous applications such as mine warfare, port and harbor security patrol, anti-piracy, search and rescue, and more.

“This is an outstanding local company that develops and produces highly innovative and exciting game-changing products with very important strategic applications,” OGES executive chairman and CEO Steve Barber stated in the news release. “We are pleased to provide batteries for their products and welcome the opportunity to work together. We at Oakridge love high-speed vehicles whether on the ground or in the water, and these products are absolutely best in class.”

MARTAC president and CEO Bruce Hanson noted his company’s high esteem for Oakridge’s technology and capabilities.

“Oakridge is an incredible company to work with. Their engineering team reviewed our applications and immediately started work on a fantastic solution that exceeded our expectations and strengthened our product offerings. It is absolutely wonderful to have a strong lithium battery manufacturing facility in the U.S.,” said Hanson. “We look forward to a long and successful relationship with the Oakridge team!”

Oakridge also recapped news from earlier this week, in which it announced its entrance into the full scale production phase of its company restructuring. The company forecasts solid revenues in January and rapid growth each month thereafter.

For more information, visit www.oakg.net

Let us hear your thoughts: Oakridge Global Energy Solutions, Inc. Message Board

Yes! It’s time for New Year’s resolutions, and the folks at Moxian have just made theirs. Moxian, Inc (OTCQB: MOXC) recently filed its Annual Report (10-K) for the financial year ending September 30, 2015, and that report revealed a lot of goodies for the festive season. Moxian has set out to serve China’s huge Online-to-Offline (O2O) market. The company has built an online platform for small- and medium-sized enterprises (SMEs) that already operate brick-and-mortar establishments to extend their marketing reach, and it has strengthened the effectiveness of that online presence by making the Moxian platform not only a marketplace where merchant clients and shoppers meet but a social media outlet where shoppers can discuss, recommend and chat. The Moxian platform is a powerful combination of online shopping bazaar and social medium. It also offers merchant clients powerful data analytics on buying patterns and other customer demographics that allow the direction of targeted advertising campaigns and promotions.

Although Moxian is a development stage company, it has been generating revenue since the latter half of 2014. The company has high operating leverage: a large proportion of costs are fixed and the variable cost of adding new customers is minimal. Consequently, most of new revenue improves the contribution margin. Management estimates that operating breakeven will be achieved with 25,000 paying merchants. At an average of $1,200 per annum in merchant fees, a merchant client base of 25,000 would deliver $30 million in annual sales.

Moxian’s game plan is to quickly add merchant clients with subscription accounts. It expects that as the number of merchant clients increases so will the base of shoppers (Users), until a critical mass is reached. At this point, the Moxian+ platform will develop an ongoing momentum. This marketing strategy has had initial success. The company was able to sign up 30,000 merchants in Shenzhen, China, for beta testing of the earlier Moxian platform, Moxian 1.0. Feedback about functionality and user experience from this trial has resulted in the development of the current platform, Moxian+. That database of 30,000 merchants is currently being targeted for conversion to paying subscriptions in the new Moxian+ platform. The prospects look good. The company was able to sign up those 30,000 merchants in Shenzhen with a sales force of 20. Now, it plans to have a sales force of 80 people by the end of 2016 in its recently opened office in Beijing. Moxian is also currently scheduling sales events in Shenzhen for the Chinese New Year season, as it did for the Christmas season, to promote its products and services to merchants. During 2016, the company plans to utilize third party distributors with an existing base of merchants to market its products.

Moxian’s balance sheet shows the company’s improving position. Net tangible assets more than doubled from $2,860,510 at 30-Sep-14 to $6,421,312 at 30-Sep-15. Cash and cash equivalents rose from $1,770,196 in 2014 to $2,398,713 in 2015. In addition, the company has been buttressed by substantial capital infusions amounting to $16,187,663, and further improvement to its capital stock is imminent. Under a subscription agreement with Beijing Xinhua Huifeng Equity Investment Centre, the company has received a deposit of $5,505,915, part payment in an agreement to sell an aggregate of 8,169,000 shares of its common stock at $1.00 per share to Xinhua Huifeng. Xinhua Huifeng was expected to exercise its rights under the agreement by December 31, 2015.

Moxian’s investor metrics support its promise. It does well in a peer comparison of development stage companies. Take 3TL Technologies Corp (OTCQB: TTMZF); this outfit operates in the consumer internet advertising sector and is a provider of social media engagement and data mining solutions. 3TL Technologies’ earnings per share (EPS) at June 30, 2015, were $(0.01), while its market capitalization was $5.3 million. Then there’s SpendSmart Networks, Inc (OTCQB: SSPC) which focuses on connecting merchants and consumers through its suite of services that includes digital engagement and mobile marketing. SpendSmart (DBA SMS Masterminds) has an EPS of $(0.15) and a market cap of $30 million. And then there’s Keek, Inc (OTCQX: KEEKF); Keek is a leading mobile video social network with more than 71 million members worldwide. Its network is accessed by the Keek app, which is available in over 190 countries across 6 global regions and in 36 languages. Keek has an EPS of $(0.22) and a market cap of $2.9 million. Compared to these tech startups, Moxian is a Jupiter among lesser planets. Even though its EPS is $(0.02), its market cap, reflecting the company’s huge potential, is over $1 billion. Moxian’s trajectory seems headed into orbit. Could it be the next Tencent Holdings?

For more information, visit the company’s website at http://ir.moxian.com/html-en/

Let us hear your thoughts: Moxian, Inc. Message Board

Traveling is a fun and enjoyable experience, especially when you are able to take your kids along to make lasting memories and interact with different cultures. However, a scary reality for parents with children who have food allergies is the possibility of rushing their little one to the emergency room due to an allergic reaction. Thankfully, in today’s Internet age of smartphone technology, information and health and safety tips are readily available in the palm of your hand.

In a recent article featured on the popular SheKnows.com website, Tara Zamani, a Nutritionist at Content Checked Holdings, Inc. (OTCQB: CNCK), provides valuable insight about the company’s suite of innovative mobile apps, and how they can help anyone avoid these potential catastrophes through awareness of food allergies in packaged food and beverages.

To view the entire article, visit http://www.sheknows.com/parenting/articles/1103389/travel-tips-for-kids-with-food-allergies.

The fun and excitement of traveling does not always have to be deterred by the fear of a food allergy reaction. The SheKnows article provides insightful tips on how to plan ahead and use common sense when dealing with allergens in various travel situations. It also suggests carrying medications with you at all times, contacting the airline ahead of time about the medications you will be traveling with, FaceTiming or Skyping with your host prior to arrival, and researching restaurants – all essential tips to make a potentially dangerous traveling experience that much more enjoyable. In addition to these tips, simply utilizing the ContentChecked app allows you to educate yourself and the people around you about potential allergens in food and beverage items you may come across.

Zamani’s contribution to SheKnows.com not only brings to light an important and relatable circumstance for people with food allergies, but also positions ContentChecked in front of an influential and wide demographic of women of all ages. SheKnows.com reaches 4,737,750 unique monthly visitors and provides daily content for women seeking advice, information, and exclusive content on entertainment, parenting, health and wellness, money, careers, dating, beauty and style.

For more information, please visit the company’s website at www.contentchecked.com

In a recent interview on ‘Business Rockstars’ with Ken Rutkowski, Content Checked Holdings, Inc.’s (OTCQB: CNCK) CEO Kris Finstad talks in depth about the company’s origins, its mission, where it is today and plans for the company’s future. A few years ago when Kris was cooking dinner for his daughter and one of her friends, the friend ended up in the emergency room due to an allergic reaction to one of the ingredients in the meal he prepared. Why did this happen? Simply because food labels often give very limited and confusing information, especially pertaining to food allergens. The ContentChecked app originated from this all too frequent and relatable instance. The app allows its users to scan a product’s bar code and determine if it is safe for consumption, as well as helps users to personalize shopping lists and make sure they purchase products that are compatible with their specific allergies and intolerances.

Kris first launched the app in Norway, accumulated 17,000 users, and gained invaluable experience with a reliable test market before making the decision to tackle the competitive U.S. market. ContentChecked is in the Food Knowledge sector and has very little competition. The company makes money through the advertisement of foods and beverages that are listed as alternatives for those products consumers scan that do not match their allergy settings.

The company has a family of mobile apps, which includes the SugarChecked app ($0.99 in the app store); the MigraineChecked app (free in the app store); and its namesake ContentChecked app (free or the premium version costs $1.99 in the app store). Each app is supported by the largest and most comprehensive food database and is updated constantly by a team of nutritionists, medical professionals and user feedback.

Kris is the principal shareholder of the company, having invested $6 million of his own money, along with raising an additional $2 million from the IPO. ContentChecked has all the pieces in place to grow and succeed, including a dedicated and knowledgeable team with a laudable purpose; high demand with very little supply and competition in its sector; a proven test market; and skin in the game.

For more information, please visit the company’s website at www.contentchecked.com

In a recent article on tech news site ReadWrite, contributor Cate Lawrence took an in-depth look at the evolution of the wearable technologies market. Currently, the wearables market is saturated with a collection of hand-based devices – such as bands, watches and jewelry – designed to service a variety of functions from tracking vital signs to informing users about text messages. In the ReadWrite article, the author asked a simple question: “What can this [device] give me that my smartphone and laptop cannot?” In the case of many of the market’s most popular and successful wearable devices – including contributions such as the Apple (NASDAQ: AAPL) Watch and the Samsung (OTC: SSNLF) Gear S – the simple answer to this question is ‘not much’. However, this could be in for a change.

Some of the most exciting wearables entering the fray in 2016 are shifting the focus away from the hand in favor of the feet. Take, for example, Nike’s (NYSE: NKE) recently unveiled Nike Mag footwear. With a design that’s eerily reminiscent of Marty McFly’s signature kicks in the Back to the Future trilogy, these prototype sneakers utilize digital technology to power specialized laces that react to the wearer’s motion. Adaptive shoe technology is just one example of a way in which the function of wearable devices can exceed the bounds of smartphones and laptops.

Another innovative device highlighted in the ReadWrite article was the GPS Smart Sole, which is marketed by GTX Corporation (OTC: GTXO). As anyone who has ever left his or her smartphone at home by mistake can attest, sometimes just remembering to take technology with you can be a considerable hurdle to overcome. The GPS Smart Sole eliminates this issue by embedding a GPS tracking device with a rechargeable battery into a comfortable shoe insert. The result is a revolutionary device that could change the way that people who provide care to individuals with cognitive conditions such as Alzheimer’s, dementia, autism and traumatic brain injuries approach their daily routines.

While remembering to pick up a cell phone on the way out the door can be extremely difficult for both children and people affected by serious cognitive conditions, studies show that individuals rarely leave the house without their shoes. This simple trend makes GTXO’s GPS Smart Sole an ingenious approach to the age old problem presented when caring for individuals with a tendency to wander. With a battery that lasts as long as three days on a single charge, GPS Smart Sole technology is expected to play a major role in improving the quality of life of people affected by these conditions.

With the novelty of wearable technology beginning to fade, developers are being forced to reimagine their collective approach toward this growing market. The result, at least to this point, has been the emergence of a collection of innovative tech devices that eloquently address otherwise difficult or inconvenient issues that affect the daily lives of thousands of consumers around the globe.

To view the full ReadWrite article, visit http://readwrite.com/2015/12/29/wearables-devices-foot-leg

For more information, visit www.gtxcorp.com

Let us hear your thoughts: GTX Corp. Message Board

NanoViricides, Inc. (NYSE MKT: NNVC) is taking a new approach to combatting some of the world’s most commercially important viral diseases through the development of nanotechnology-based biomimetic anti-viral medicines called NanoViricides®. These microscopic agents are specially designed to fool viruses into attaching to them, much like they attach to the receptors of human cells. However, once attached, NanoViricides wrap around the virus, trapping the infectious organism and destroying its coat proteins. Without coat proteins, viruses are unable to bind to cells. In other words, the company’s innovative antiviral technology renders targeted viruses completely innocuous and effectively destroyed.

Although NNVC’s licensed technology may be effective in combatting a host of viruses – including HIV/AIDS, cold sores and genital herpes infection, viral eye diseases and dengue viruses – the company’s leading product candidate is being developed for the treatment of severe influenza. Injectable FluCide™ is a novel, first-in-class drug for which NNVC has filed a pre-IND application. Late last year, the company reported that it is also advancing preclinical studies for HerpeCide™, which it expects to serve as the cornerstone for topical drugs designed to control herpes virus outbreaks for a number of indications. In the months to come, NNVC intends to continue work on both Injectable FluCide and HerpeCide in an effort to initiate clinical stage testing in the near future.

“The topical HerpeCide program is developing in parallel with our injectable FluCide,” Eugene Seymour, MD, MPH, chief executive officer of NNVC, stated in a news release. “The HerpeCide program is likely to move faster toward clinical trials, because of the inherent advantages in the nature of topical drug development.”

According to company data, the current market size for herpes simplex virus treatments is in excess of $2 billion annually. Additionally, NNVC estimates that a drug that offers superior results to those provided by existing therapies could result in significantly expanded market size. Existing therapies against herpes simplex virus – including acyclovir, famciclovir and chemically-related drugs – must be taken orally or by injection and are largely ineffective as topical agents.

By developing HerpeCide in the form of topical drugs to control herpes outbreaks for oral lesions, genital lesions and shingle outbreaks, NNVC is targeting an immense market. According to the Centers for Disease Control and Prevention, about one out of every six people between the ages of 14 and 49 have genital herpes. Similarly, roughly 80 percent of all Americans have oral herpes.

As NNVC continues to advance its clinical pipeline, the company is in a favorable position to promote sustainable industry growth. For prospective shareholders, the combination of a strong nanomedicine intellectual property portfolio and a promising development pipeline makes NNVC an intriguing investment opportunity moving forward.

For more information, visit www.nanoviricides.com

Ovarian cancer is the eighth most common form of cancer in the United States, according to the Centers for Disease Control and Prevention, and it’s the fifth leading cause of cancer deaths. This dangerous form of cancer begins as a growth of abnormal malignant cells in the ovaries before spreading to other sites within the body. Although we still don’t know exactly what causes ovarian cancers, we do know that some factors make women more likely to develop epithelial ovarian cancer during their lifetime. According to the American Cancer Society, both inherited genetic mutations and acquired genetic changes can place women at a heightened risk of developing this dangerous condition.

For women in an elevated risk category for ovarian cancer, regular screening and, if necessary, early detection can play a major role in overall health and wellbeing. If diagnosed in its early stages, ovarian cancer is an extremely survivability illness. When discovered in stage one, approximately 92 percent of ovarian cancer cases surpass the recorded five-year survival milestone. Despite this statistic, the average five-year survival rate for ovarian cancer is just 44 percent. This is because only 15 percent of ovarian cancers are currently diagnosed during stage one, according to Healthline.

Avant Diagnostics, Inc. (OTCQB: AVDX) is on a mission to improve the survivability of ovarian cancer by giving women access to more effective early detection technology. The company’s pre-symptomatic ovarian cancer screening test, OvaDx®, is a leading breakthrough in the field of ovarian cancer diagnostics. OvaDx is a sophisticated microarray-based test that measures the activation of the immune system in blood samples in response to early stage ovarian tumor cell development. In clinical research, the test has indicated high sensitivity and specificity for all types and stages of ovarian cancer.

Following FDA approval, Avant intends to offer OvaDx as an elective test for women in the elevated risk category for ovarian cancer, as well as those seeking greater wellness. As the market’s first large panel screening test for ovarian cancer, OvaDx is expected to greatly improve the early diagnosis rate of ovarian cancer and, as a result, advance the survivability of this deadly disease.

For more information, visit www.avantdiagnostics.com

Let us hear your thoughts: Avant Diagnostics, Inc. Message Board

VolitionRx (NYSE MKT: VNRX) is a life sciences company focused on developing simple to use, yet effective diagnostic tests for cancer and other conditions by identifying and measuring nucleosomes in the bloodstream or other bodily fluid – an indication that disease is present. In recent months the company has made impressive strides toward its goal to bring its diagnostic products to market by obtaining patent protection for its technologies and leveraging invaluable personnel expertise.

VolitionRx today announced Dr. Jason Terrell, MD as its full-time chief medical officer and head of U.S. operations. Dr. Terrell has served in a part-time capacity in these roles since March 2013, and, on a full-time basis, he will continue to lead and coordinate VolitionRx’s U.S. operations in preparation for initial market entry of the company’s NuQ® blood tests for cancer in the U.S. and worldwide.

“The recent results of clinical trials by VolitionRx have been so compelling that we feel the time is right to employ a full-time head of U.S. operations in preparation for introducing our NuQ® blood tests to the U.S. market,” said Cameron Reynolds, president and chief executive officer of VolitionRx. “In the past few months, we have secured U.S. patents to protect our key technologies and are making strong progress toward our goal of commercialization of NuQ® products. As a doctor holding medical licenses in 14 states across the U.S., Jason brings comprehensive experience and knowledge regarding the U.S. regulatory environment and competitive situation, which should be invaluable in developing VolitionRx’s strategy to enter the U.S. market and gain FDA approval of our NuQ® cancer tests. In his role as VolitionRx’s chief medical officer, Jason will continue to bring first-hand insights of a medical practitioner and a deep understanding of patient requirements.”

Through his part-time tenure with VolitionRx, Dr. Terell is well-familiar with the potential of VolitionRx’s NuQ® tests and what they could mean for oncology patients.

“In addition to now demonstrating more than 90% accuracy in detecting colorectal, pancreatic and lung cancers, NuQ® tests are non-invasive for patients, requiring only a single drop of blood, and are simple for doctors to administer on existing clinical laboratory instruments,” said Dr. Terrell. “As a doctor myself, it’s very exciting to be involved with bringing NuQ® tests to market as they have the potential to make major advances in the early detection of cancer, lead to a greater number of individuals being screened for various cancers, and significantly improve patient outcomes.”

Dr. Terrell earned his medical degree at the University of Texas and affiliate MD Anderson Cancer Center, with expertise in both clinical medicine and the laboratory diagnostics business. He has a strong grounding in diagnostics and product commercialization and has both executive and board directorship experience with publicly traded companies in the biotechnology and pharmaceutical industries. Dr. Terrell previously served on the board of directors and as medical director for CDEX Inc., a company developing drug validation technology. In addition, over the last six years, Dr. Terrell has built and sold multiple private diagnostic laboratories and currently serves as a National Franchise Corporate Medical Director for Any Lab Test Now, which includes overseeing more than 70 franchises in 14 states.

Dr. Terrell earned a Bachelor of Science Biochemistry from Hardin-Simmons University, where he graduated Summa Cum Laude, receiving the Holland Medal of Honor as the top graduate in the School of Science and Mathematics. He then attended the University of Texas at Houston Medical School and affiliate MD Anderson Cancer Center to become Doctor of Medicine. He undertook his General Medicine Internship, and Anatomic and Clinical Pathology Residency at Texas Tech University Health Sciences Center. In February 2014, Dr. Terrell was the recipient of the Outstanding Young Alumni Award from Hardin-Simmons University.

For more information visit www.volitionrx.com

Social media and business marketing go hand in hand for small- and medium-sized businesses trying to get over the many hurdles associated with business development and growth. Moxian, Inc. (OTCQB: MOXC) offers an affordable, efficient vehicle for small- and medium-sized businesses in Asia and the Middle East to increase their users while also networking with other merchants across the region.

Moxian employs a social marketing platform, known as “MO-Promo,” which is an online sales promotion website for its clients’ businesses. The platform consists of the following constituents: 1) Social Customer Relationship Management (SCRM); 2) MO-Points; 3) online games; 4) a social networking website known as MO-Zone; and 5) Social Loyalty Program which rewards MO-Pal users or customers who are using MO-Points. The way MO-Promo works is quite ingenius and very common with some of the most popular revenue-generating apps currently used in the social media marketplace. Users are rewarded with MO-Points for free by playing games and winning prizes that are sponsored by Moxian and client merchants.

Gathering user information, offering rewards and ensuring smart ad placement are essential when conducting an effective marketing campaign. Plus, if you can have fun while doing it, there is really nothing else to think about. Moxian is using a proven business model and applying it to an untapped market in Asia and the Middle East. Consistent growth of its users and merchants, along with attainable growth targets for 2016, has Moxian in the spotlight of companies to watch with nearly unlimited upside potential.

The Asian market is growing rapidly. China is expected to become the world’s largest economy by 2020 and India is expected to rank fourth on the global economic scale by 2025. Unsurprisingly, Asia is considered a key strategic growth market in various fields. This is not just because of the region’s vast population – more than half the current world population lives in Asia – but also because the area continues to develop, innovate and gain more influence on a global scale, according to the Novagraaf.

For more information, visit the company’s website at http://ir.moxian.com/html-en/

Let us hear your thoughts: Moxian, Inc. Message Board